Alkermes (ALKS)
Develops and sells neuroscience medicines spanning addiction, psychiatry and sleep disorders.
Something off on this page? Send us feedback.
Sells proprietary U.S. neuroscience medicines for addiction, schizophrenia, bipolar I disorder and narcolepsy, led by VIVITROL, ARISTADA, LYBALVI and LUMRYZ. Product sales are supplemented by manufacturing and royalties from partner-marketed medicines, while clinical development focuses on sleep and other neurological disorders.
Develops and commercializes neuroscience medicines across addiction, psychiatry and sleep. The U.S. proprietary portfolio includes VIVITROL for alcohol and opioid dependence; ARISTADA and ARISTADA INITIO for schizophrenia; LYBALVI for schizophrenia and bipolar I disorder; and LUMRYZ, a once-at-bedtime narcolepsy treatment added through the Avadel acquisition. Clinical programs target sleep and other neurological disorders.
Revenue comes primarily from U.S. sales of these branded medicines, supplemented by manufacturing and royalties from partner-marketed long-acting INVEGA products, VUMERITY and legacy products. Drug discovery, formulation, clinical development, manufacturing and commercial capabilities support the portfolio through lifecycle management. Results depend on demand and market access for a concentrated U.S. product portfolio, compliant manufacturing and supply, partner product sales, and successful clinical and regulatory execution.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 28, 2026 | Piper Sandler | Reiterate | Rating: —Target: $45 | Target: $65 |
| Jul 20, 2026 | Stifel Nicolaus | Target | Target: $36 | Target: $63 |
| Jul 2, 2026 | Mizuho Securities | Target | Target: $45 | Target: $65 |
| Jun 29, 2026 | B of A Securities | Downgrade | ||
| Jun 18, 2026 | Needham | Reiterate | Rating: —Target: $50 | Target: $54 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $656.6M · Total debt $1.57B · Total assets $4.39B · Shareholders' equity $1.81B
- Revenue
- $496.0M
- Operating income
- $18.4M
- Net income
- $501.0K
No dividends on record.
| Institutions | 107.47% | 180.29M shares | |
|---|---|---|---|
| 437 holders · as of Jun 30, 2026 | |||
| Insiders | 0.65% | 1.10M shares | |
| 14 holders · as of Sep 3, 2026 | |||
| Adds to | 108.12% | ||
167.76M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 108.12%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 17.43% | 29.24M | as of Jun 30, 2026 |
Baker Bros. Advisors LPInstitution | 5.97% | 10.01M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.66% | 9.49M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.46% | 9.16M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.48% | 7.52M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 3, 2026 | David Joseph Gaffin | officer: EVP, CLO, Alkermes, Inc. | −2,034 | $48.01 |
| Sep 1, 2026 | Craig C. Hopkinson | officer: EVP R&D, Chief Medical Officer | −9,000 | $46.99 |
| Aug 17, 2026 | Christian Todd Nichols | officer: SVP, Chief Commercial Officer | −7,576 | $49.23 |
| Aug 3, 2026 | David Joseph Gaffin | officer: EVP, CLO, Alkermes, Inc. | −2,034 | $48.58 |
| Aug 3, 2026 | Craig C. Hopkinson | officer: EVP R&D, Chief Medical Officer | −9,000 | $48.58 |
- Johnson & Johnson
Broad schizophrenia overlap across LAI and CAPLYTA franchises
- Indivior
OUD franchise peer to VIVITROL via SUBLOCADE and SUBOXONE
- Teva (ADR)
LAI antipsychotic and future generic VIVITROL overlap
- Jazz Pharmaceuticals
Oxybate sleep-medicine incumbent against LUMRYZ
- AbbVie
Branded oral antipsychotic overlap with LYBALVI
- Bristol-Myers Squibb
Focused oral schizophrenia overlap through COBENFY
- Harmony Biosciences
Narcolepsy overlap through WAKIX wake-promoting therapy
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alkermes | $44.11 | −0.17% | $7.41B | 115.4 | — | 4.4 | +27.0% |
| Johnson & Johnson | $267.82 | −0.61% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| Indivior | $36.26 | +2.04% | $4.43B | 12.7 | 8.0 | 3.3 | +13.6% |
| Teva (ADR) | $39.35 | −1.77% | $46.66B | 66.8 | 14.0 | 2.7 | −0.8% |
| Jazz Pharmaceuticals | $240.81 | −0.27% | $15.17B | 16.5 | 9.6 | 3.3 | +15.6% |
| AbbVie | $265.98 | +0.57% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Bristol-Myers Squibb | $62.70 | +0.13% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Harmony Biosciences | $41.96 | −0.33% | $2.44B | 13.7 | 10.5 | 2.5 | +30.3% |
| Median | 16.5 | 10.5 | 3.3 | +10.2% |